All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Survey to be completed independently by HCPs (neurologists treating patients with MS and MS specialist nurses) and patients/caregivers.
Dec 02, 2021
Sep 30, 2024
18 Years and older (Adult, Older Adult)
Physicians will be considered eligible for the survey if they meet the following screening criteria:
Care for relapsing MS (RMS) patients
Personally prescribed disease modifying therapies to MS patients, and;
Have prescribed Mayzent (siponimod) in at least 1 SPMS patient.
Nurses will be considered eligible for the survey if they:
Provide supportive care for RMS patients
Have initiated and/or managed the use of Mayzent (siponimod) in at least 1 SPMS patient.
Patient inclusion criteria include:
- Have been initiated onto Mayzent (siponimod) to treat their MS since reimbursement